Literature DB >> 12771031

CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis.

Rayjean J Hung1, Paolo Boffetta, Jürgen Brockmöller, Dorota Butkiewicz, Ingolf Cascorbi, Margie L Clapper, Seymour Garte, Aage Haugen, Ari Hirvonen, Sisko Anttila, Ivan Kalina, Loïc Le Marchand, Stephanie J London, Agneta Rannug, Marjorie Romkes, Jan Salagovic, Bernadette Schoket, Laura Gaspari, Emanuela Taioli.   

Abstract

Polymorphisms for genes encoding the metabolic enzymes cytochrome P450 1A1 (CYP1A1) and glutathione S-transferase M1 (GSTM1) might contribute to the variability in individual susceptibility to lung cancer. The role of CYP1A1 and GSTM1 in lung carcinogenesis might be more important at low levels of exposure to carcinogens. Non-smokers represent a population at low exposure, however, they are often overlooked because of the small number of cases. We therefore conducted a pooled analysis of 14 case-control studies on lung cancer in Caucasian non-smokers with comparable information on genetic polymorphisms included in the International Collaborative Study on Genetic Susceptibility to Environmental Carcinogens. We pooled the raw data from a total of 302 cases and 1631 controls with random effects models. We also evaluated the possibility of inclusion bias and conducted influence analyses. The odds ratio (OR) of lung cancer for the variant CYP1A1 Ile(462)Val polymorphism (Ile/Val, Val/Val) was 2.99 [95% confidence interval (95%CI) 1.51-5.91]; this effect was stronger on lung adenocarcinoma (OR 4.85, 95%CI 2.03-11.6). After excluding outlying or imprecise studies, we did not observe a significant effect of the CYP1A1 MspI (T(3801)C) polymorphism or GSTM1 null genotype (OR 1.20, 95%CI 0.89-1.63). Furthermore, our analyses suggested a combined effect of the CYP1A1 Ile(462)Val polymorphism and GSTM1 null genotype. The OR for the combination of the CYP1A1 Ile(462)Val variant and GSTM1 null genotype was 4.67 (95%CI 2.00-10.9) compared with the concurrent presence of the CYP1A1 wild-type and GSTM1 non-null genotype. We did not observe a modification of the effect of the GSTM1 null genotype according to exposure to environmental tobacco smoke and urban/rural residence. Our study therefore suggests that the CYP1A1 Ile(462)Val variant allele might play a role in lung carcinogenesis among non-smokers, possibly in combination with the GSTM1 null genotype.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12771031     DOI: 10.1093/carcin/bgg026

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  44 in total

1.  Metabolism of [D10]phenanthrene to tetraols in smokers for potential lung cancer susceptibility assessment: comparison of oral and inhalation routes of administration.

Authors:  Yan Zhong; Jing Wang; Steven G Carmella; J Bradley Hochalter; Diane Rauch; Andrew Oliver; Joni Jensen; Dorothy K Hatsukami; Pramod Upadhyaya; Cheryl Zimmerman; Stephen S Hecht
Journal:  J Pharmacol Exp Ther       Date:  2011-04-22       Impact factor: 4.030

Review 2.  CYP1A1 MspI polymorphism and susceptibility to lung cancer in the Chinese population: an updated meta-analysis and review.

Authors:  Xin Wang; Kai Yue; Li-Ran Hao
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Quantitation of N-acetyl-S-(9,10-dihydro-9-hydroxy-10-phenanthryl)-L-cysteine in human urine: comparison with glutathione-S-transferase genotypes in smokers.

Authors:  Pramod Upadhyaya; Priyanka Rao; J Bradley Hochalter; Zhong-Ze Li; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2006-09       Impact factor: 3.739

Review 4.  Nutrigenomics: integrating genomic approaches into nutrition research.

Authors:  Lynnette R Ferguson
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

5.  Analysis of r-7,t-8,9,c-10-tetrahydroxy-7,8,9,10-tetrahydrobenzo[a]pyrene in human urine: a biomarker for directly assessing carcinogenic polycyclic aromatic hydrocarbon exposure plus metabolic activation.

Authors:  Yan Zhong; Steven G Carmella; J Bradley Hochalter; Silvia Balbo; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2010-11-04       Impact factor: 3.739

6.  Gene-environment interactions associated with CYP1A1 MspI and GST polymorphisms and the risk of upper aerodigestive tract cancers in an Indian population.

Authors:  Soya Sisy Sam; Vinod Thomas; K S Reddy; Gopalakrishnan Surianarayanan; Adithan Chandrasekaran
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-10       Impact factor: 4.553

7.  Polymorphisms of CYP1A1, GSTM1 and GSTT1 Loci as the Genetic Predispositions of Oral Cancers and Other Oral Pathologies: Tobacco and Alcohol as Risk Modifiers.

Authors:  Sumana Chatterjee; Soujatya Dhar; Bani Sengupta; Ashish Ghosh; Manas De; Sumit Roy; Sila Chakrabarti
Journal:  Indian J Clin Biochem       Date:  2010-08-25

8.  Combined effects of CYP1A1 MspI and GSTM1 genetic polymorphisms on risk of lung cancer: an updated meta-analysis.

Authors:  Wen Li; Li-Qiang Song; Jian Tan
Journal:  Tumour Biol       Date:  2014-06-18

9.  Preferential glutathione conjugation of a reverse diol epoxide compared to a bay region diol epoxide of phenanthrene in human hepatocytes: relevance to molecular epidemiology studies of glutathione-s-transferase polymorphisms and cancer.

Authors:  Stephen S Hecht; Jeannette Zinggeler Berg; J Bradley Hochalter
Journal:  Chem Res Toxicol       Date:  2009-03-16       Impact factor: 3.739

10.  CYP1A1 gene polymorphisms increase lung cancer risk in a high-incidence region of Spain: a case control study.

Authors:  Carmen San Jose; Agustin Cabanillas; Julio Benitez; Juan Antonio Carrillo; Mercedes Jimenez; Guillermo Gervasini
Journal:  BMC Cancer       Date:  2010-08-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.